Pasithea Therapeutics Corp. (KTTAW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysts estimate Earnings Per Share (EPS) of $-1.50 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-12.69 vs est $-1.50 (missed -745.7%). 2025: actual $-2.91 vs est $-0.68 (missed -327.9%). Analyst accuracy: 18%.
